Cancer Therapies Should Be Held To Higher Bar In Maintenance Setting, ODAC Says

In their review of Merck/Ariad’s Taltorvic (ridaforolimus) for sarcoma patients with stable disease, members of FDA’s Oncologic Drugs Advisory Committee suggested the nature of maintenance therapy necessitates that efficacy be more robust, and toxicities less of a concern, than in the treatment setting.

More from US FDA Performance Tracker

More from Regulatory Trackers